Patent Application
20230040061
The emergence and spread of SARS-CoV-2 initiated a worldwide pandemic. The complete genome sequence of this novel coronavirus was determined and released the following year. Over a year later, the first genetic systems for SARS-CoV-2 were published and current methods for site specific manipulation of viral RNA involved a cumbersome multistep process that is time consuming and prone to error.
The disclosure relates to programmable RNA editing using a type III CRISPR complex. For example, a type III CRISPR-Cas complex may be engineered to edit RNA. The type III CRISPR-Cas complex may be a type III-A Csm complex derived from Streptococcus thermophilus (SthCsm). The engineered CRISPR-Cas complex may be used to make sequence-specific modifications to RNA. The term “sequence-specific modification” may refer to changing RNA at a location that is targeted to a specific sequence of the RNA. The modifications may include a deletion in which a target portion is removed from the RNA, a replacement in which a target portion is removed and replaced with a synthetic RNA, base modifications and/or other changes to the RNA.
Type III CRISPR complexes rely on CRISPR RNA (crRNA)-guided nucleases that specifically cleave complementary RNA at six nucleotide intervals. To engineer a type III CRISPR complex, the RNA cleavage activity of a type III CRISPR complex is engineered to excise a sequence-specific region of target RNA or introduce a sequence-specific cut. For targeted deletion of the target portion of RNA, the RNA is repaired using splint ligation. Such repair may be in vitro. The result is an edited RNA with the target portion removed. For replacement of the target portion, the RNA a synthetic RNA complement is splinted prior ligation, resulting in the target portion being replaced with the synthetic RNA.
For testing and validation, examples herein will describe modifying a type III-A CRISPR RNA-guided nuclease for sequence-specific cleavage of the SARS-CoV-2 genome. The type III cleavage reaction is performed in vitro using purified viral RNA, resulting in sequence-specific cleavage at a single position or excision of 6, 12, 18 or 24 nucleotides. Ligation of the cleavage products is facilitated by a DNA splint that bridges the excision and RNA ligase is used to link the RNA products before transfection into mammalian cells. The SARS-CoV-2 RNA is infectious and standard plaque assays are used to recover viral clones. It should be noted, however, that a type III CRISPR-Cas complex may be engineered to make site-specific modifications to other RNA targets, whether genomic RNA or other types of RNA based on the disclosures herein. Collectively, the disclosures herein may be used for sequence-specific editing of RNA, which may be applicable for RNA viruses and gene therapy in general.
In some examples, the techniques described herein relate to a method of editing a ribonucleic acid (RNA) molecule, the method including: cleaving the RNA molecule with an engineered type III Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) complex to excise a target portion from the RNA molecule, the type III CRISPR complex including: a CRISPR RNA (crRNA) sequence that is programmed to be complementary to a target sequence of the RNA molecule; and a crRNA-guided nuclease that specifically cleaves the RNA molecule at the target portion when the engineered type III CRISPR complex is bound to the RNA molecule; and ligating cleaved ends of the RNA molecule that flank the excised target portion. Thus, the RNA molecule is programmatically edited based on the excised target portion and the ligated cleaved ends.
In some examples, the techniques described herein relate to a method, wherein ligating the cleaved ends of the RNA molecule includes inserting zero additional nucleotides between both ends and ligating together both ends of the RNA molecule to result in deletion of the target portion.
In some examples, the techniques described herein relate to a method, wherein ligating the cleaved ends of the RNA molecule includes inserting one or more additional modified or non-modified nucleotides between both ends and ligating together the one or more additional nucleotides and both ends of the RNA molecule to result in replacement of the target portion with the one or more additional nucleotides.
In some examples, the techniques described herein relate to a method, wherein ligating the cleaved ends of the RNA molecule includes using a nucleic acid splint that bridges both ends of the RNA molecule.
In some examples, the techniques described herein relate to a method, wherein the nucleic acid splint includes a deoxyribonucleic acid (DNA) splint.
In some examples, the techniques described herein relate to a method, wherein ligating the cleaved ends of the RNA molecule includes: inserting one or more additional nucleotides between both ends and ligating together the one or more additional nucleotides and both ends of the RNA molecule to result in replacement of the target portion with the one or more additional nucleotides, and wherein the nucleic acid splint includes a sequence that is complementary to a sequence of the one or more additional nucleotides.
In some examples, the techniques described herein relate to a method, wherein the engineered type III CRISPR complex includes a Csm complex.
In some examples, the techniques described herein relate to a method, wherein the crRNA-guided nuclease specifically cleaves the RNA molecule at intervals of one or more nucleotides.
In some examples, the techniques described herein relate to a method, wherein the intervals of one or more nucleotides includes intervals of six nucleotides.
In some examples, the techniques described herein relate to a method, wherein a number of the intervals is dependent on a length of the crRNA sequence.
In some examples, the techniques described herein relate to a method, wherein the length of the crRNA sequence is 40 nucleotides, the intervals of one or more nucleotides includes intervals of six nucleotides, and the number of the intervals is between three and four.
In some examples, the techniques described herein relate to a method, wherein the RNA molecule includes a viral genome, and the edited RNA molecule includes an edited virion.
In some examples, the techniques described herein relate to a method, wherein the virus includes the SARS-CoV-2 virus.
In some examples, the techniques described herein relate to a method, wherein the excising is performed in vitro, the method further including: recovering the edited virion; and transfecting the recovered edited virion into a host.
In some examples, the techniques described herein relate to a method, further including: how to engineer/program the type III CRISPR complex.
In some examples, the techniques described herein relate to a method of generating an engineered type III Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) complex to edit ribonucleic acid (RNA), including: generating a plurality of expression vectors including: (i) a CRISPR array having a natural or engineered CRISPR RNA (crRNA) transcript and a Cas subunit that processes pre-CRISPR transcripts into mature crRNA guide (i.e., Cas6 or Cas7-11), and (ii) a plurality of protein subunits of the type III CRISPR complex; co-transfecting the plurality of expression vectors into a host; inducing expression of the plurality of expression vectors in the host; and purifying the expressed plurality of expression vectors from the host.
In some examples, the techniques described herein relate to a method, further including: selecting purified products based on an expected size of the crRNA guide.
In some examples, the techniques described herein relate to a method, wherein the expected size is 46 nucleotides.
In some examples, the techniques described herein relate to a method, wherein the plurality of expression vectors includes: a first expression vector including the CRISPR array; a second expression vector including Cas10 and Csm2 subunits; and a third expression vector including Csm3, Csm4, and Csm5 subunits.
In some examples, the techniques described herein relate to a method, wherein the plurality of expression vectors includes: a first expression vector including the CRISPR array; a second expression vector including the gene for Cas7-11.
Features of the present disclosure may be illustrated by way of example and not limited in the following figure(s), in which like numerals indicate like elements, in which:
The disclosure relates to RNA editing using an engineered type III CRISPR complex. Many CRISPR RNA-guided nucleases are routinely used for sequence-specific manipulation of DNA. However, analogous methods for editing RNA have yet to be established. The use of CRISPR systems for editing RNA have been restricted to in vivo base editors that are incapable of deleting or inserting specific sequences by design. Thus, what is needed are RNA editing systems that enable specific RNA editing to address SARS-CoV-2 and other viral RNA pathogens, and more generally to programmatically edit any RNA for gene therapy or other purposes.
“RNA editing”, “editing RNA”, and similar terms may refer to deliberately modifying RNA. For example, RNA editing may include deleting a portion of the RNA that is intended to be removed, replacing the portion of the RNA with a synthetic RNA sequence that is intended to replace the portion of the RNA, adding synthetic RNA so that the edited RNA includes the synthetic RNA without replacement (even though some examples may remove RNA then add back the removed RNA), deleting one portion of RNA while adding a synthetic RNA, and/or otherwise modifying the RNA in an intentional manner. In some examples, RNA editing may be performed via a type III-E CRISPR Cas7-11 complex. RNA editing may be performed in vitro, in which case the edited RNA may be introduced into a host. RNA may include genomic RNA (such as viral genomic RNA) and/or other RNA molecules.
The term “engineered”, and similar terms may refer to a deliberate generation of a system that is otherwise non-naturally occurring. Such engineering may include introducing one or more mutations to a genetic sequence, designing a genetic sequence, combining a set of components such as proteins and detection components where such combination does not occur in nature, and/or otherwise generating a non-naturally occurring system to edit nucleic acid such as RNA.
The engineered type III CRISPR complex may include a nuclease that cleaves RNA at specific sites guided by a CRISPR RNA (crRNA) sequence, which may be programmable. The term “programmatic”, “programmable”, and similar terms may refer to designing the engineered type III CRISPR complex to perform RNA editing. In particular, the programmable crRNA sequence refers to being designed to guide the engineered type III CRISPR complex to a specific target portion of interest in the RNA. For example, sequence specific targeting of crRNAs may be performed by designing synthetic spacer sequences. The synthetic spacer sequences may be between 20 and 60 nucleotides long that separate the repeat sequences or end with a self-cleaving ribozyme, such that the crRNA is processed into a short (20-100 nt) crRNA that is incorporated into an assembly of one or more Cas proteins, which together form a ribonucleoprotein complex that stably binds and cleaves RNAs that are complementary to the guide (spacer) sequence. The spacer sequences are designed to be complementary to a target sequence and intentionally designed to avoid complementarity to other “non-target” RNAs. In some examples, crRNA-guides are designed to include a protospacer flanking sequence (PFS) that facilitates binding, cleavage, or cyclic nucleotide synthesis. In other examples, the PFS is any sequence that is not complementary to the 5′ repeat sequence of the crRNA. The programmable crRNA sequence may therefore facilitate specific cleavage of the RNA at one or more specific sites, enabling programmatic RNA editing. One example of an engineered type III CRISPR complex that may be used is a Csm complex, which is a type III-A CRISPR complex that has RNase activity. The Csm complex may be a SthCsm, derived from S. thermophilus.
Various examples described herein will refer to editing a viral RNA genome, such as the RNA genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, any RNA molecule may be edited using the engineered type III CRISPR complex and methods disclosed herein.
The purified target RNA may be incubated with the engineered type III CRISPR complex. The programmable crRNA sequence may hybridize to the target RNA, binding the engineered type III CRISPR to the target RNA. The bound engineered type III CRISPR complex may cleave the RNA in vitro using a crRNA-guided nuclease that cleaves the target RNA at a target site guided by the crRNA sequence. At the target site, the crRNA-guided nuclease may cleave the target RNA at N-nucleotide increments. In particular, the crRNA-guided nuclease may cleave the target RNA at a single positon or in increments of 6 nucleotides. The number of increments may depend on the length of the crRNA and the composition or stoichiometry of Cas proteins in the complex. Typically, though not necessarily, the number of nucleases-active subunits may be three to four such that a total of 18 to 24 nucleotides are excised.
Following cleavage, the RNA fragments are treated to make the cleaved ends compatible with an RNA ligase for repair. For example, the RNA fragments may be treated with T4 PNK to make the cleaved ends biochemically compatible with T4 RNA ligase 1.
The treated RNA fragments may be annealed to a nucleic acid oligonucleotide, which functions as a nucleic acid splint that bridges the two RNA fragments. The nucleic acid oligonucleotide may be an RNA oligonucleotide and/or a deoxyribonucleic acid (DNA) oligonucleotide. Thus, the nucleic acid splint may be an RNA splint and/or a DNA splint. The splinted structure (treated RNA fragments and annealed RNA splint and/or DNA splint) is then treated with a ligase that recognizes doubled stranded structures and repairs cleaved ends. For example, the ligase may be T4 RNA ligase 1, which recognizes the double stranded structure of the splinted structure and forms a phosphodiester bond between the cleaved genome fragments to thereby ligate the ends. It should be noted that such ligation may result in a deleted locus of interest (an example of which is illustrated in
In should be noted that in some type III systems (such as type III-A or type III-B), the nuclease is part of one subunit in the complex that assembles along the crRNA. Thus, the longer the crRNA, the more nuclease subunits and the larger number of cleavage events. Not all cleavage events occur at the same time so cleavage may be heterogeneous (i.e., some crRNA-guided complexes will cleave the target 4 times while others cleave twice). The nucleic acid splints are designed to enrich specific cleavage events by flanking specific sequences on either side of specific cleavage products. Some type III systems (type III-E) consist of a single polypeptide. These systems generally cleave the target at two positions that are separated by 6-nucleotides, but like other type III systems, the RNase active sites can be mutated, creating a cleavage defective complex that binds but does not cleave the target RNA or type III-E complexes can be engineered by mutating one of the two active sites so that they cleave the target RNA at one specific location.
To purify the type III-A Csm complex with guides designed to target SARS-CoV-2, a synthetic CRISPR was generated. The synthetic CRISPR includes four identical 36-nucleotide “spacers” that are flanked by the Streptococcus thermophilus CRISPR repeats. This CRISPR array is under the control of a T7 inducible promoter. Included in this cloning vector is the S. thermophilus gene for Cas6, which processes the crRNA transcript into a mature crRNA in some Type III CRISPR systems. The protein subunits of the Csm complex are sometimes split onto two expression vectors. Cas10 and Csm2 are on the pACYC-duet vector, while Csm3, Csm4, and Csm5 are on pRSF-1b vector. The Csm3 gene includes an N-terminus Strep-2 tag which is used for strep column chromatography. These three cloning vectors are co-transfected into E. coli BL21 (DE3) cells. The expression of these genes is under the control of a T7 promoter and is induced using Isopropyl β-d-1-thiogalactopyranoside (IPTG). After growth and induction of the expression vectors, Csm complexes were purified from these cells by strep column chromatography followed by size exclusion chromatography.
RNA targeting by the engineered type III-A Csm complex (also referred to herein as “Csm complex”) is strictly dependent on complementarity to the crRNA guide and does not rely on a protospacer adjacent motif (PAM), which simplifies guide design and eliminates constrains imposed by PAM distribution. Thus, the Csm complex can be directed to excise any 6, 12, 18 or 24 nucleotide sequence within an RNA genome. Other lengths of nucleotide sequences may be excised as well. The guide sequence is designed to have 36 nucleotides complementary to the target RNA. After transcription, the nascent crRNA transcript is processed by Cas6 and/or other nucleases to result mature crRNAs, the primary species being a 28 nucleotide crRNA composed of a 20 nucleotide guide and an 8 nucleotide 5′ sequence derived from the repeat of the CRISPR. There is some heterogeneity in this processing, which results in a mix of differently sized mature crRNAs. The Csm complex assembles along the mature crRNA, as such, a smaller crRNA results in the assembly of a smaller complex. In this system, the most Csm complexes excise 12 to 24 nucleotides at the target region.
Cleavage of target RNA is performed by incubating the purified Csm complex with target RNA in vitro. SthCsm complex targeting the SARS-CoV-2 genome was incubated with purified viral genome in a 2:1 complex-to-genome molar ratio in a buffer composed of 20 mM HEPES (pH 7.5), 50 mM KCl, 0.1 mg/ml BSA, 10 mM Mg-acetate, and 1 U/uL murine RNAse inhibitor for 30 minutes at 37° C. This cleavage excises 6, 12, 18 or 24 nucleotides at the target sequence, dependent upon the crRNA associated with the Csm complex. Following cleavage, the genome fragments are purified using the Monarch RNA Cleanup Kit (NEB).
Following cleavage with Csm, the genome fragments are treated with T4 PNK (available from New England Biolabs®). Csm is a metal dependent nuclease that leave 2′-3′ cyclic phosphate on the 3′ cleavage product and hydroxyl on the 5′ end. The 2′-3′ cyclic phosphate is replaced with 2′ and 3′ hydroxyls by treating the cleaved genome fragments with T4 PNK in 1× PNK buffer at 37° C. for 40 minutes. The reaction is then supplemented with ATP to 1 mM and incubated at 37° C. for an additional 40 minutes to replace the 5′ hydroxyl group with a 5′ monophosphate group. Following PNK treatment, the genome fragments are purified using the MONARCH RNA Cleanup Kit (available from New England Biolabs®).
Splint ligation first involves the annealing of the RNA fragments to a DNA oligonucleotide that bridges the cleaved region by base pairing to the two cleavage products. This splinted RNA-DNA hybrid is treated with T4 RNA ligase 1, which connected the two-cleavage product with a phosphodiester bond.
The DNA oligonucleotide splint is mixed with PNK-treated genome fragments in a 1:1 splint-to-genome molar ratio in 1× T4 RNA ligase buffer. To anneal the fragments to the splint, the mixture is heated to 95° C. for 2 minutes, then slowly ramped down to 4° C. over 45 minutes in a thermocycler. Following annealing of the splint to the cleaved genome fragments, the RNA:DNA hybrid is treated with T4 RNA ligase 1 (available from New England Biolabs®) following manufacturer protocol in 1× ligase buffer supplemented with 10% PEG 8000 and 1 U/ul murine RNAse inhibitor. The reaction is incubated at 25° C. for 1 hour. The reaction is then treated with 1 uL TURBO DNase (ThermoFisher Scientific) and incubated for 15 minutes at 37° C. to remove the DNA splint. RNA is then purified using the MONARCH RNA Cleanup Kit (available from New England Biolabs®). This results in an edited RNA genome with the target RNA removed.
This cleavage and splint ligation approach to RNA editing may also be applied further to replace a region of a viral RNA genome with a synthetic RNA sequence of interest. To accomplish this, Csm complexes with multiplexed guides (i.e. two Csm complexes with guides recognizing two sites in the genome) are used to cleave the RNA genome at two sites flanking the region to be replaced. The resulting cleavage products are then treated with T4 PNK, as described above, and mixed with a synthetic RNA molecule. Two DNA splints that were designed to hybridize with the genome fragments and the synthetic RNA are then annealed to the RNA molecules. This structure is then treated with T4 RNA ligase 1 which seals the nicks between the genome fragments and the synthetic RNA, resulting in directed integration of synthetic RNA into a viral genome. This approach to RNA editing is outlined in
To validate this approach, we created a synthetic CRISPR for the type III A Csm complex from Streptococcus thermophilus that is designed to target the ORF7a gene of SARS-CoV-2. Cleavage efficiency is measured by RT-qPCR using primer pairs that flank the cleavage site. Using this approach, we routinely cleave >98% of the target RNA. Following cleavage, the products are reconnected using splint ligation. The efficiency of ligation is measured using the same RT-qPCR assay. We routinely achieve ligation efficiencies of ˜25%. To verify that the approach results in the expected deletion, we deep sequenced across the edited region of the RNA. The sequencing data reveals that the primary product is an RNA containing the desired 18-nucleotide deletion,
Another possible iteration of this RNA editing procedure depends on host RNA ligases encoded by mammalian cells. Specifically, RNA editing may be mediated by the mammalian tRNA ligase complex. This suggests that Csm-mediated RNA editing might be possible in vivo, and that mammalian tRNA ligase complex could eliminate the dependence on PNK treatment, splint annealing, and in vitro ligation steps.
Collectively, these results demonstrate that RNA editing by Csm, followed by splint ligation is an effective procedure that results in the expected edited product. Csm cleavage is programmable and completely PAM independent, as such, we expect this RNA editing technology to be generalizable to any RNA molecule, with a major application being facile editing of RNA viruses. This approach is unique, as no other methods have been reported which accomplish editing of RNA via programmable cleavage and ligation of an RNA molecule in vitro. We anticipate that nuclease defective type III complexes could also serves as platforms that target base editors, and other RNA modifying enzymes to specific RNA sequences by design, which would enable genetic and epigenetic editing without cleavage.
The crRNA sequence may be a CRISPR guide sequence that is engineered to be complementary to a locus of the nucleic acid, such as the RNA target. The crRNA sequence may be selected based on one or more conserved regions of the target nucleic acid or other region of interest. For example, different genomes of the SARS-CoV-2 virus (or other RNA target) may be aligned with one another to identify conserved regions. Generally speaking, regions having a greater alignment (fewer base pair differences and longer alignment lengths) than regions having lesser alignment are better candidates for generating a complementary sequence to use as the CRISPR guide sequence.
The crRNA sequence may be designed based on conserved regions across different samples of the SARS-CoV-2, different strains of the SARS-CoV-2, and/or other samples available for the SARS-CoV-2. Such conserved sequence may be determined based on sequence alignments. A pairwise match may be considered when an alignment quality of the pairwise match is sufficient to determine that aligned portions of two sequences represent a conservation of the nucleotides in the sequences across genomes of SARS-CoV-2 (or other target). The alignment quality may be specified as having a minimum overlap of at least about 1 base, 2 bases, 4 bases, 4 bases, 5 bases, 10 bases, 15 bases, 40 bases, 25 bases, 40 bases, 45 bases, 40 bases, 45 bases, 50 bases, 55 bases, 60 bases, 65 bases, 70 bases, 75 bases, 80 bases, 85 bases, 90 bases, 95 bases, or 100 bases. Alternatively, or additionally, the alignment quality may be based on a minimum alignment identity of at least about 5%, 10%, 15%, 40%, 25%, 40%, 45%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more. In some cases, a criterion may require at least a 25-nt overlap with at least about 70% identity.
In this example, the sequencing encoding the SARS-CoV-2 nucleocapsid (N) and ORF7a genes were selected to serve as the basis for generating the CRISPR guide sequence. Examples of the CRISPR guide sequence include SEQ ID NO. 1-SEQ ID NO. 4.
Sequences
A sequence listing, named “065869-0570003_US_SEQUENCE_LISTING.xml”, created Jul. 7, 2022,” 4.66 bytes, in XML format accompanies this application. The sequence listing is incorporated by reference in its entirety herein for all purposes.
thermophilus to edit N-gene of
thermophilus to edit ORF7a-gene of
Desulfonema ishimotonii to edit N-
Desulfonema ishimotonii to edit
After purification the complex is mixed with 1.2× concentration of pre-mature crRNA (66 nt) that includes full sequence of the direct repeat (35 nt) from CRISPR locus and 31 nt spacer sequence that is reverse complementary to the target sequence. Cas7-11 polyprotein is then incubated with pre-mature crRNA in a buffer composed of 20 mM HEPES (pH 7.5), 50 mM KCl, 0.1 mg/ml BSA, 10 mM Mg-acetate, and 1 U/uL murine RNAse inhibitor for 30 minutes at 37° C. This reaction promotes complexing of Cas7-11 protein with the crRNA and crRNA processing that involves trimming the direct repeat sequence leaving a 15 nt 5′-tag.
Target RNA may be obtained from a subject. For example, the target RNA may be an RNA of an organism that infects a host organism. In particular, the target RNA may be an RNA genome of a virus that has infected the subject. In another example, the target RNA may be the RNA of the subject. A subject may refer to an animal, such as a mammalian species (preferably human) or avian (e.g., bird) species, or other organism, such as a plant. More specifically, a subject can be a vertebrate, e.g., a mammal such as a mouse, a primate, a simian or a human. Animals include farm animals, sport animals, and pets. A subject can be a healthy individual, an individual that has symptoms or signs or is suspected of having a disease or a predisposition to the disease, or an individual that is in need of therapy or suspected of needing therapy.
A genetic modification or mutation in the context of an engineered system may refer to an alteration, variant or polymorphism in a nucleic acid that may result in altered or disabled functionality of a corresponding protein. Such alteration, variant or polymorphism can be with respect to a reference genome, the subject or other individual. Variations include one or more single nucleotide variations (SNVs), insertions, deletions, repeats, small insertions, small deletions, small repeats, structural variant junctions, variable length tandem repeats, and/or flanking sequences, CNVs, transversions, gene fusions and other rearrangements may also be considered forms of genetic variation. A variation can be a base change, insertion, deletion, repeat, copy number variation, transversion, or a combination thereof.
A “polynucleotide”, “nucleic acid”, “nucleic acid molecule”, or “oligonucleotide” may each refer to a polymer of nucleosides (including deoxyribonucleosides, ribonucleosides, or analogs thereof) joined by inter-nucleosidic linkages. Typically, a polynucleotide comprises at least three nucleosides. Oligonucleotides often range in size from a few monomeric units, e.g. 3-4, to hundreds of monomeric units. Whenever a polynucleotide is represented by a sequence of letters, such as “AUGCCUG,” it will be understood that the nucleotides are in 5′ to 3′ order from left to right and that “A” denotes adenosine, “C” denotes cytidine, “G” denotes guanosine, and “U” denotes uracil, unless otherwise noted. The letters A, C, G, and U (or “T” denoting thymine in DNA) may be used to refer to the bases themselves, to nucleosides, or to nucleotides comprising the bases, as is standard in the art.
All patent filings, websites, other publications, sequence listings, accession numbers and the like cited above or below are incorporated by reference in their entirety for all purposes to the same extent as if each individual item were specifically and individually indicated to be so incorporated by reference.
If different versions of a sequence are associated with an accession number at different times, the version associated with the accession number at the effective filing date of this application is meant. The effective filing date means the earlier of the actual filing date or filing date of a priority application referring to the accession number if applicable. Likewise, if different versions of a publication, website or the like are published at different times, the version most recently published at the effective filing date of the application is meant unless otherwise indicated. Any feature, step, element, embodiment, or aspect of the disclosure can be used in combination with any other unless specifically indicated otherwise. Although the present disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
This application claims the benefit of priority of U.S. Provisional Application No. 63/219,722, filed on Jul. 8, 2021, which is incorporated by reference herein for all purposes.
| Number | Date | Country | |
|---|---|---|---|
| 63219722 | Jul 2021 | US |
